CF
INSY

Cypress Funds’s Insys Therapeutics, Inc. INSY Stock Holding History

Cypress Funds’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-135,584
Closed -$1.75M – 34
2016
Q2 		$1.75M Buy
+135,584
New +$1.98M 0.41% 23

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cypress Funds's INSY Position: Q3 2016 in Review

Cypress Funds sold out of Insys Therapeutics, Inc. (INSY) in Q3 2016, closing a stake of 135,584 shares — an estimated $1.75M sold.

Cypress Funds first reported a position in INSY in Q2 2016 and held it in 1 quarter. The position peaked at $1.75M in Q2 2016. 138 funds tracked by Wall St. Rank hold INSY as of Q3 2016.

  • Cypress Funds reported no remaining Insys Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Cypress Funds sold 135,584 Insys Therapeutics, Inc. shares in Q3 2016, an estimated $1.75M.
  • Cypress Funds first reported a position in Insys Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • Cypress Funds's Insys Therapeutics, Inc. position peaked at $1.75M in Q2 2016.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2016.

Based on Cypress Funds's 13F filing for Q3 2016, filed 7 Nov 2016.